ETF Holdings Breakdown of CORT

Stock Name	Corcept Therapeutics Incorporated
Ticker	CORT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US2183521028
LEI	529900EO9LUTFMZ7FF90

CORT institutional holdings

The adjusted close for CORT on 2025-11-12 was 78.39

The following institutional investment holdings of CORT have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 69,329 USD 5,434,700 -0.8% 78.39

2025-11-12 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 27,444 -0.3% USD 2,151,335 -1.1% 78.39

2025-11-12 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 1,496 USD 117,271 -0.8% 78.39

2025-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 544 USD 42,644 -0.8% 78.39

Total = 98,813 USD 7,745,950
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	69,329	USD 5,434,700 -0.8%	78.39
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	27,444 -0.3%	USD 2,151,335 -1.1%	78.39
2025-11-12	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,496	USD 117,271 -0.8%	78.39
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	544	USD 42,644 -0.8%	78.39
Total =	98,813	USD 7,745,950

News associated with CORT

Canaccord Genuity Group Boosts Corcept Therapeutics (NASDAQ:CORT) Price Target to $140.00: Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price target raised by Canaccord Genuity Group from $137.00 to $140.00 in a research note published on Wednesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on CORT. Piper Sandler […] - 2025-09-11 04:46:10
Brokerages Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $134.50: Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in […] - 2025-09-11 02:30:51
Charles Schwab Investment Management Inc. Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT): Charles Schwab Investment Management Inc. trimmed its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 1.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,031,724 shares of the biotechnology company’s stock after selling 19,836 shares during the quarter. […] - 2025-08-12 05:24:52
LPL Financial LLC Purchases 1,502 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT): LPL Financial LLC boosted its position in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 2.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,184 shares of the biotechnology company’s stock after purchasing an additional 1,502 shares during the quarter. LPL […] - 2025-08-11 05:34:55
Federated Hermes Inc. Lowers Position in Corcept Therapeutics Incorporated (NASDAQ:CORT): Federated Hermes Inc. decreased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 7.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,872 shares of the biotechnology company’s stock after selling 998 shares during the period. Federated Hermes […] - 2025-08-07 04:52:51
Corcept Therapeutics (NASDAQ:CORT) Given New $137.00 Price Target at Canaccord Genuity Group: Corcept Therapeutics (NASDAQ:CORT – Free Report) had its price objective decreased by Canaccord Genuity Group from $142.00 to $137.00 in a research report released on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock. CORT has been the subject of several other research reports. Truist Financial set a […] - 2025-08-04 04:27:04
2,863 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Private Advisor Group LLC: Private Advisor Group LLC bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor bought 2,863 shares of the biotechnology company’s stock, valued at approximately $327,000. Several other large investors also recently added to or reduced their stakes in the business. Parallel Advisors […] - 2025-08-01 05:01:09
IFP Advisors Inc Acquires 679 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT): IFP Advisors Inc boosted its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 1,150.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 738 shares of the biotechnology company’s stock after buying an additional 679 shares during the quarter. IFP Advisors Inc’s holdings in Corcept Therapeutics were worth $84,000 as of its […] - 2025-07-31 04:28:57
Universal Beteiligungs und Servicegesellschaft mbH Acquires New Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT): Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 1st quarter, HoldingsChannel reports. The firm bought 18,542 shares of the biotechnology company’s stock, valued at approximately $2,118,000. Other institutional investors have also added to or reduced their stakes in the company. Corient Private […] - 2025-07-31 04:28:49
Choreo LLC Sells 203 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT): Choreo LLC lowered its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 4.4% during the first quarter, HoldingsChannel reports. The firm owned 4,384 shares of the biotechnology company’s stock after selling 203 shares during the quarter. Choreo LLC’s holdings in Corcept Therapeutics were worth $501,000 as of its most recent SEC […] - 2025-07-28 04:38:57
Y Intercept Hong Kong Ltd Has $1.03 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT): Y Intercept Hong Kong Ltd cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 78.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,987 shares of the biotechnology company’s stock after selling 33,031 shares during the […] - 2025-07-25 07:26:49
Allianz Asset Management GmbH Cuts Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT): Allianz Asset Management GmbH lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 0.6% in the first quarter, HoldingsChannel.com reports. The firm owned 162,194 shares of the biotechnology company’s stock after selling 906 shares during the quarter. Allianz Asset Management GmbH’s holdings in Corcept Therapeutics were worth $18,526,000 at the end of […] - 2025-07-25 06:34:53
Victory Capital Management Inc. Boosts Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT): Victory Capital Management Inc. raised its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 24.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,418 shares of the biotechnology company’s stock after purchasing an additional 18,389 shares during the quarter. Victory Capital Management […] - 2025-07-25 05:09:10
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $317,066.20 in Stock: Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 4,315 shares of the firm’s stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $73.48, for a total transaction of $317,066.20. Following the sale, the insider directly owned 17,705 shares of the company’s […] - 2025-07-23 05:14:52
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider William Guyer Sells 4,379 Shares: Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider William Guyer sold 4,379 shares of the firm’s stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $73.48, for a total transaction of $321,768.92. Following the completion of the sale, the insider owned 5,487 shares of […] - 2025-07-23 05:14:50
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $138.25 Average PT from Analysts: Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) have received an average recommendation of “Buy” from the five analysts that are covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the […] - 2025-07-23 02:02:55
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 3,877 Shares: Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Joseph Douglas Lyon sold 3,877 shares of Corcept Therapeutics stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $73.48, for a total value of $284,881.96. Following the completion of the transaction, the insider directly owned 10,066 shares in […] - 2025-07-22 08:24:59
Corcept Therapeutics Incorporated (NASDAQ:CORT) CEO Joseph K. Belanoff Sells 615 Shares: Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) CEO Joseph K. Belanoff sold 615 shares of the business’s stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $73.69, for a total value of $45,319.35. Following the completion of the sale, the chief executive officer owned […] - 2025-07-22 08:24:58
Sean Maduck Sells 473 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock: Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 473 shares of Corcept Therapeutics stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $73.44, for a total value of $34,737.12. Following the transaction, the insider directly owned 17,705 shares in the company, valued at […] - 2025-07-22 08:24:58
New York State Common Retirement Fund Reduces Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT): New York State Common Retirement Fund decreased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 9.8% during the 1st quarter, Holdings Channel.com reports. The firm owned 35,563 shares of the biotechnology company’s stock after selling 3,862 shares during the period. New York State Common Retirement Fund’s holdings in Corcept Therapeutics were worth […] - 2025-07-22 07:10:53
Cwm LLC Purchases 2,231 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT): Cwm LLC grew its position in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 22.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,194 shares of the biotechnology company’s stock after purchasing an additional 2,231 shares during the period. Cwm LLC’s holdings in Corcept […] - 2025-07-21 05:18:50
Arizona State Retirement System Lowers Position in Corcept Therapeutics Incorporated (NASDAQ:CORT): Arizona State Retirement System cut its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 1.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,995 shares of the biotechnology company’s stock after selling 275 shares during the period. Arizona State Retirement […] - 2025-07-17 05:12:54
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Alps Advisors Inc.: Alps Advisors Inc. reduced its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 33.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,207 shares of the biotechnology company’s stock after selling 3,071 shares during the quarter. Alps Advisors Inc.’s holdings in Corcept […] - 2025-07-15 06:59:57
Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer: (RTTNews) - Corcept Therapeutics Incorporated (CORT), a commercial-stage biopharma company focused on cortisol modulation, has submitted a New Drug Application - NDA to the U.S. FDA for relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer - 2025-07-14 14:03:25
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by New York State Teachers Retirement System: New York State Teachers Retirement System reduced its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 8.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 117,932 shares of the biotechnology company’s stock after selling 10,300 shares during the […] - 2025-07-04 05:31:04
Robeco Institutional Asset Management B.V. Acquires Shares of 3,107 Corcept Therapeutics Incorporated (NASDAQ:CORT): Robeco Institutional Asset Management B.V. acquired a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,107 shares of the biotechnology company’s stock, valued at approximately $355,000. Several other institutional investors also […] - 2025-07-03 05:08:53
Oppenheimer & Co. Inc. Boosts Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT): Oppenheimer & Co. Inc. grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 39.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,246 shares of the biotechnology company’s stock after buying an additional 6,246 shares during […] - 2025-06-27 05:36:54
Envestnet Portfolio Solutions Inc. Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT): Envestnet Portfolio Solutions Inc. bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 5,074 shares of the biotechnology company’s stock, valued at approximately $580,000. Several other institutional investors and hedge funds also recently […] - 2025-06-27 04:37:02
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Position Decreased by Blue Trust Inc.: Blue Trust Inc. cut its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 20.0% in the 1st quarter, HoldingsChannel.com reports. The fund owned 2,345 shares of the biotechnology company’s stock after selling 585 shares during the quarter. Blue Trust Inc.’s holdings in Corcept Therapeutics were worth $268,000 at the end of […] - 2025-06-24 05:03:03
Park Avenue Securities LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT): Park Avenue Securities LLC acquired a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the 1st quarter, Holdings Channel reports. The fund acquired 2,266 shares of the biotechnology company’s stock, valued at approximately $259,000. Other large investors have also made changes to their positions in the company. Vanguard Group Inc. […] - 2025-06-16 04:40:48

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.